Abivax (NASDAQ:ABVX) Hits New 12-Month High – What’s Next?

Abivax SA Sponsored ADR (NASDAQ:ABVX)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $139.62 and last traded at $138.72, with a volume of 4152856 shares. The stock had previously closed at $114.94.

Wall Street Analyst Weigh In

ABVX has been the topic of several analyst reports. Truist Financial set a $140.00 price objective on Abivax in a research note on Monday, November 24th. JMP Securities upped their price target on Abivax from $95.00 to $114.00 and gave the company a “market outperform” rating in a research report on Thursday, September 25th. BTIG Research lifted their price objective on Abivax from $112.00 to $120.00 and gave the company a “buy” rating in a report on Monday, October 6th. Wolfe Research raised shares of Abivax to a “strong-buy” rating in a report on Thursday, November 6th. Finally, Guggenheim reissued a “buy” rating and set a $175.00 price target on shares of Abivax in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $128.73.

Abivax Price Performance

The stock has a fifty day moving average of $109.59 and a 200-day moving average of $73.24. The firm has a market capitalization of $10.81 billion, a P/E ratio of -80.18 and a beta of 0.49. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million for the quarter. Equities analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Abivax

Several hedge funds and other institutional investors have recently made changes to their positions in ABVX. EverSource Wealth Advisors LLC raised its position in shares of Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares during the last quarter. First Horizon Corp bought a new stake in Abivax during the 3rd quarter worth about $36,000. Bank of America Corp DE lifted its position in Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the period. Hantz Financial Services Inc. bought a new position in shares of Abivax in the 3rd quarter valued at about $52,000. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after purchasing an additional 2,595 shares during the last quarter. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.